Antiproliferative activity of IL-27 on melanoma

Journal of Immunology

Volumn 180, Issue 10, 2008, Pages 6527-6535

  Yoshimoto, Takayuki ^a   Morishima, Noriko ^a   Mizoguchi, Izuru ^a   Shimizu, Motomu ^c   Nagai, Hiroshi ^b   Oniki, Shuntaro ^b   Oka, Masahiro ^b   Nishigori, Chikako ^b   Mizuguchi, Junichiro ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 130; INTERLEUKIN 12; INTERLEUKIN 27; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PHENYLALANINE; PROTEIN WSX 1; RECEPTOR SUBUNIT; SMALL INTERFERING RNA; STAT1 PROTEIN; STAT3 PROTEIN; TYROSINE; UNCLASSIFIED DRUG; CYTOKINE RECEPTOR; HLA ANTIGEN CLASS 1; IL27 PROTEIN, MOUSE; IL27RA PROTEIN, MOUSE; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN DERIVATIVE; STAT1 PROTEIN, MOUSE; STAT3 PROTEIN, MOUSE;

ANIMAL CELL; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; DOSE RESPONSE; GROWTH INHIBITION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; ANIMAL; APOPTOSIS; BIOSYNTHESIS; DRUG EFFECT; EXPERIMENTAL MELANOMA; FLOW CYTOMETRY; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERFERON REGULATORY FACTOR-1; INTERFERON REGULATORY FACTORS; INTERLEUKINS; MELANOMA, EXPERIMENTAL; MICE; RECEPTORS, CYTOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; TRANSFECTION;

EID: 45549106117     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.10.6527     Document Type: Article

References (52)

1. + T cells. Immunity 16: 779-790.
2. Pflanz, S., L. Hibbert, J. Mattson, R. Rosales, E. Vaisberg, J. F. Bazan, J. H. Phillips, T. K. McClanahan, R. de Waal Malefyt, and R. A. Kastelein. 2004. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J. Immunol. 172: 2225-2231.
3. Takeda, A., S. Hamano, A. Yamanaka, T. Hanada, T. Ishibashi, T. W. Mak, A. Yoshimura, and H. Yoshida. 2003. Cutting edge: role of IL-27AVSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J. Immunol. 170: 4886-4890.
4. Hibbert, L., S. Pflanz, R. De Waal Malefyt, and R. A. Kastelein. 2003. IL-27 and IFN-α signal via Stat1 and Stat3 and induce T-Bet and IL-12Rβ2 in naive T cells. J. Interferon Cytokine Res. 23: 513-522.
5. Villarino, A., L. Hibbert, L, Lieberman, E. Wilson, T. Mak, H. Yoshida, R. A. Kastelein, C. Saris, and C. A. Hunter. 2003. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 19: 645-655.
6. + T cells. J. Immunol. 173: 3871-3877.
7. Villarino, A. V., J. Larkin, III, C. J. Saris, A. J. Caton, S. Lucas, T. Wong, F. J. de Sauvage, and C. A. Hunter. 2005. Positive and negative regulation of the IL-27 receptor during lymphoid cell activation. J. Immunol. 174: 7684-7691.
8. Hunter, C. A. 2005. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat. Rev. Immunol. 5: 521-531.
9. Hisada, M., S. Kamiya, K. Fujita, M. L. Belladonna, T. Aoki, Y. Koyanagi, J. Mizuguchi, and T. Yoshimoto. 2004. Potent antitumor activity of interleukin 27. Cancer Res. 64: 1152-1156.
10. Chiyo, M., O. Shimozato, L. Yu, K. Kawamura, T. Iizasa, T. Fujisawa, and M. Tagawa. 2005. Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. Int. J. Cancer 115: 437-442.
11. + T cells. J. Immunol. 173: 7170-7182.
12. Oniki, S., H. Nagai, T. Horikawa, J. Furukawa, M. L. Belladonna, T. Yoshimoto, I. Hara, and C. Nishigori. 2006. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res. 66: 6395-6404.
13. Angiolillo, A. L., C. Sgadari, D. D. Taub, F. Liao, J. M. Farber, S. Maheshwari, H. K. Kleinman, G. H. Reaman, and G. Tosato. 1995. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med. 182: 155-162.
14. Sgadari, C, A. L. Angiolillo, and G. Tosato. 1996. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 87: 3877-3882.
15. Strieter, R. M., P. J. Polverini, S. L. Kunkel, D. A. Arenberg, M. D. Burdick, J. Kasper, J. Dzuiba, J. Van Damme, A. Walz, D. Marriott, et al. 1995. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 270: 27348-27357.
16. Shimizu, M., M. Shimamura, T. Owaki, M. Asakawa, K. Fujita, M. Kudo, Y. Iwakura, Y. Takeda, A. D. Luster, J. Mizuguchi, and T. Yoshimoto. 2006. Antiangiogenic and antitumor activities of IL-27. J. Immunol. 176: 7317-7324.
17. Pang, K. R., J. J. Wu, D. B. Huang, S. K. Tyring, and S. Baron. 2005. Biological and clinical basis for molecular studies of interferons. Methods Mol. Med. 116: 1-23.
18. Chada, S., R. Ramesh, and A. M. Mhashilkar. 2003. Cytokine- and chemokine-based gene therapy for cancer. Curr. Opin. Mol. Ther. 5: 463-474.
19. Ferrantini, M., and F. Belardelli. 2000. Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications. Semin. Cancer Biol. 10: 145-157.
20. Gutterman, J. U. 1994. Cytokine therapeutics: lessons from interferon α. Proc. Natl. Acad. Sci. USA 91: 1198-1205.
21. Nastala, C. L., H. D. Edington, T. G. McKinney, H. Tahara, M. A. Nalesnik, M. J. Brunda, M. K. Gately, S. F. Wolf, R. D. Schreiber, W. J. Storkus, et al. 1994. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. 153: 1697-1706.
22. Colombo, M. P., and G. Trinchieri. 2002. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13: 155-168.
23. Coughlin, C. M., K. E. Salhany, M. S. Gee, D. C. LaTempIe, S. Kotenko, X. Ma, G. Gri, M. Wysocka, J. E. Kim, L. Liu, et al. 1998. Tumor cell responses to IFNγ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9: 25-34.
24. Coughlin, C. M., K. E. Salhany, M. Wysocka, E. Aruga, H. Kurzawa, A. E. Chang, C. A. Hunter, J. C. Fox, G. Trinchieri, and W. M. Lee. 1998. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J. Clin. Invest. 101: 1441-1452.
25. Sangfelt, O., S. Erickson, and D. Grander. 2000. Mechanisms of interferon-induced cell cycle arrest. Front. Biosci. 5: D479-D487.
26. Detjen, K. M., K. Farwig, M. Welzel, B. Wiedenmann, and S. Rosewicz. 2001. Interferon γ inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis. Gut 49: 251-262.
27. Hobeika, A. C, W. Etienne, P. E. Cruz, P. S. Subramaniam, and H. M. Johnson. 1998. IFNγ induction of p21WAFI in prostate cancer cells: role in cell cycle, alteration of phenotype and invasive potential. Int. J. Cancer 77: 138-145.
28. Ruiz-Ruiz, C., C. Ruiz de Almodovar, A. Rodriguez, G. Ortiz-Ferron, J. M. Redondo, and A. Lopez-Rivas. 2004. The up-regulation of human caspase-8 by interferon-γ in breast tumor cells requires the induction and action of the transcription factor interferon regulatory factor-1. J. Biol. Chem. 279: 19712-19720.
29. Tomita, Y., V. Bilim, N. Hara, T. Kasahara, and K. Takahashi. 2003. Role of IRF-1 and caspase-7 in IFN-γ enhancement of Fas-mediated apoptosis in ACHN renal cell carcinoma cells. Int. J. Cancer 104: 400-408.
30. Merchant, M. S., X. Yang, F. Melchionda, M. Romero, R. Klein, C. J. Thiele, M. Tsokos, H. U. Kontny, and C. L. Mackall. 2004. Interferon γ enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma. Cancer Res. 64: 8349-8356.
31. Papageorgiou, A., L. Lashinger, R. Millikan, H. B. Grossman, W. Benedict, C. P. Dinney, and D. J. McConkey. 2004. Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells. Cancer Res. 64: 8973-8979.
32. Ruiz-Ruiz, C, C. Munoz-Pinedo, and A. Lopez-Rivas. 2000. Interferon-γ treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res. 60: 5673-5680.
33. Yoshimoto, T., T. Yoshimoto, K. Yasuda, J. Mizuguchi, and K. Nakanishi. 2007. IL-27 suppresses Th2 cell development and Th2 cytokines production from polarized Th2 cells: a novel therapeutic way for Th2-mediated allergic inflammation. J. Immunol. 179: 4415-4423.
34. Yoshimoto, T., K. Okada, N. Morishima, S. Kamiya, T. Owaki, M. Asakawa, Y. Iwakura, F. Fukai, and J. Mizuguchi. 2004. Induction of IgG2a class switching in B cells by IL-27. J. Immunol. 173: 2479-2485.
35. Yoshimoto, T., M. Furuhata, S. Kamiya, M. Hisada, H. Miyaji, Y. Magami, K. Yamamoto, H. Fujiwara, and J. Mizuguchi. 2003. Positive modulation of IL-12 signaling by sphingosine kinase 2 associating with the IL-12 receptor β 1 cytoplasmic region. J. Immunol. 171: 1352-1359.
36. Yoshimoto, T., Y. Takahama, C. R. Wang, T. Yoneto, S. Waki, and H. Nariuchi. 1998. A pathogenic role of IL-12 in blood-stage murine malaria lethal strain Plasmodium berghei NK65 infection. J. Immunol. 160: 5500-5505.
37. Owaki, T., M. Asakawa, S. Kamiya, K. Takeda, F. Fukai, J. Mizuguchi, and T. Yoshimoto. 2006. IL-27 suppresses CD28-medicated IL-2 production through suppressor of cytokine signaling 3. J. Immunol. 176: 2773-2780.
38. Matsumoto, M., T. Seya, S. Kikkawa, S. Tsuji, K. Shida, M. Nomura, M. Kurita-Taniguchi, H. Ohigashi, H. Yokouchi, K. Takami, et al. 2001. Interferon γ-producing ability in blood lymphocytes of patients with lung cancer through activation of the innate immune system by BCG cell wall skeleton. Int. Immunopharmacol. 1: 1559-1569.
39. Egwuagu, C. E., W. Li, C. R. Yu, M. Che Mei Lin, C. C. Chan, T. Nakamura, and A. B. Chepelinsky. 2006. Interferon-γ induces regression of epithelial cell carcinoma: critical roles of IRF-1 and ICSBP transcription factors. Oncogene 25: 3670-3679.
40. Miyamoto, M., T. Fujita, Y. Kimura, M. Maruyama, H. Harada, Y. Sudo, T. Miyata, and T. Taniguchi. 1988. Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-β gene regulatory elements. Cell 54: 903-913.
41. Tanaka, N., M. Ishihara, and T. Taniguchi. 1994. Suppression of c-myc or fosB-induced cell transformation by the transcription factor IRF-1. Cancer Lett. 83: 191-196.
42. Nozawa, H., E. Oda, K. Nakao, M. Ishihara, S. Ueda, T. Yokochi, K. Ogasawara, Y. Nakatsuru, S. Shimizu, Y. Ohira, et al. 1999. Loss of transcription factor IRF-1 affects tumor susceptibility in mice carrying the Ha-ras transgene or nullizygosity for p53. Genes Dev. 13: 1240-1245.
43. Tamura, T., M. Ishihara, M. S. Lamphier, N. Tanaka, I. Oishi, S. Aizawa, T. Matsuyama, T. W. Mak, S. Taki, and T. Taniguchi. 1995. An IRF-1-dependent pathway of DMA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature 376: 596-599.
44. Nishizuka, Y. 2001. The protein kinase C family and lipid mediators for transmembrane signaling and cell regulation. Alcohol Clin. Exp. Res. 25: 3S-7S.
45. Denning, M. F., Y. Wang, B. J. Nickoloff, and T. Wrone-Smith. 1998. Protein kinase Cδ is activated by caspase-dependent proteolysis during ultraviolet radiation-induced apoptosis of human keratinocytes. J. Biol. Chem. 273: 29995-30002.
46. Deb, D. K., A. Sassano, F. Lekmine, B. Majchrzak, A. Verma, S. Kambhampati, S. Uddin, A. Rahman, E. N. Fish, and L. C. Platanias. 2003. Activation of protein kinase C δ by IFN-γ. J. Immunol. 171: 267-273.
47. DeVries, T. A., R. L. Kalkofen, A. A. Matassa, and M. E. Reyland. 2004. Protein kinase Cδ regulates apoptosis via activation of STATI. J. Biol. Chem. 279: 45603-45612.
48. Owaki, T., M. Asakawa, N. Morishima, K. Takeda, F. Fukai, J. Mizuguchi, and T. Yoshimoto. 2008. STAT3 is indispensable to IL-27-mediated cell proliferation but not to IL-27-induced Th1 differentiation and suppression of proinflammatory cytokine production. J. Immunol. 180: 2903-2911.
49. Yoshida, H., S. Hamano, G. Senaldi, T. Covey, R. Faggioni, S. Mu, M. Xia, A. C. Wakeham, H. Nishina, J. Potter, et al. 2001. WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity 15: 569-578.
50. Owaki, T., M. Asakawa, N. Morishima, K. Hata, F. Fukai, M. Matusi, J. Mizuguchi, and T. Yoshimoto. 2005. A role for IL-27 in early regulation of Th1 differentiation. J. Immunol. 175: 2191-2200.
51. + T cell generation with enhanced granzyme B expression by IL-27. J. Immunol. 175: 1686-1693.
52. Car, B. D., V. M. Eng, J. M. Lipman, and T. D. Anderson. 1999. The toxicology of interleukin-12: a review. Toxicol. Pathol. 27: 58-63.